News & Press Releases Swedish

Scandinavian ChemoTech AB genomför ytterligare en riktad nyemission och tillförs cirka 2,5 miljoner kronor

Scandinavian ChemoTech AB (publ) (“ChemoTech” eller “Bolaget”) offentliggör härmed att Bolaget har genomfört en riktad nyemission som tillför Bolaget cirka 2,5 miljoner kronor. Kapitaltillskottet ska användas till återbetalning av lån.

Read more

Scandinavian ChemoTechs dotterbolag Vetiqure AB inleder sin marknadsföring i USA

Som ett led i den förstudie som pågår i USA inför lanseringen av bolagets unika TSE (Tumörspecifik Elektroporation) teknologi, avsett för behandling av husdjur som drabbats av cancer, planerar Vetiqure AB att medverka i ett antal Veterinärkonferenser under hösten.

Read more

Scandinavian ChemoTech genomför en riktad nyemission och tillförs cirka 18 miljoner kronor

Scandinavian ChemoTech AB (publ) (“ChemoTech” eller “Bolaget”) offentliggör härmed att Bolaget har genomfört en riktad nyemission som tillför Bolaget ca 18 miljoner före transaktionskostnader. Kapitaltillskottet möjliggör en uppväxling av Bolagets långsiktiga strategi.

Read more

News & Press Releases English

Scandinavian ChemoTech AB is carrying out another directed new share issue and will receive approximately MSEK 2.5

Scandinavian ChemoTech AB (publ) (“ChemoTech” or “the Company”) hereby announces that the Company has carried out a directed new share issue which will provide the Company with approximately MSEK 2.5. The capital injection will be used to repay loans.

Read more

Scandinavian ChemoTech's subsidiary Vetiqure AB begins its marketing in the US

As part of the feasibility study underway in the US ahead of the launch of the company's unique TSE (Tumour Specific Electroporation) technology, intended for the treatment of pets affected by cancer, Vetiqure AB plans to participate in a number of Veterinary Conferences during the autumn.

Read more

Scandinavian ChemoTech is carrying out a directed new share issue and will receive approximately MSEK 18

Scandinavian ChemoTech AB (publ) (“ChemoTech” or “the Company”) hereby announces that the Company has carried out a directed new share issue which will provide the Company with approximately MSEK 18 before transaction costs. The capital injection enables an upshift of the Company's long-term strategy.

Read more

ChemoTech Videos

Nydanande TSE-teknologi ökar den lokala effekten av cellgiftbehandling

ChemoTech presents for its upcoming Annual General meeting 24 May 2021. Spoken language is Swedish but the presentation is in English.

ChemoTech answers questions from the shareholders; Part 1 (Swedish)

CEO Mohan Frick presenting at Erik Penser Bank Bolagsdag (Swedish)

Erik Penser Bank interview with CEO Mohan Frick (Swedish)

Company Presentation of the Q3 report (Swedish) 11th of November 2020

Company Presentation (Swedish) 27th of October 2020

Videos from 2019

Share Day in Gothenburg, November 4 2019 (Swedish)

Videos from 2018

Share analysis ChemoTech Q2 2018 (Swedish)

Share Day in Malmö on May 22, 2018 (Swedish)

Our foundation

Our profound knowledge in Electroporation forms the starting point for the company’s existing product and R&D projects : IQwave™ specially desinged for both TSE- Tumour Specific Electroporation and the first generation electrochemotherapy for the treatment of a range of different types of tumours.

Our research focus

Our aim is to document the effects of elctrochemotherapy for pain management for cancer patients, an area with significant unmet medical need.